The Comparison of Strategies to PREPARE Severely CALCified Coronary Lesions Trial (PREPARE-CALC)
Launched by SEGEBERGER KLINIKEN GMBH · Jul 16, 2015
Trial Information
Current as of May 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Clinical inclusion criteria
- • Age above 18 years and consentable
- • Angiographically proven coronary artery disease
- • Anginal symptoms and/or reproducible ischemia in the target area by ECG, functional stress testing or fractional flow reserve
- • Written informed consent
- • 2. Angiographic inclusion criteria
- • De-novo lesion in a native coronary artery
- • Target reference vessel diameter between 2.25 and 4.0 mm by visual estimation
- • Luminal diameter reduction of 50-100% by visual estimation
- • Severe calcification of the target lesion
- Exclusion Criteria:
- • 1. Clinical exclusion criteria
- • Myocardial infarction (within 1 week)
- • Decompensated heart failure
- • Limited long term prognosis due to other conditions
- • 2. Angiographic exclusion criteria
- • Target lesion is in a coronary artery bypass graft
- • Target lesion is an in-stent restenosis
- • Target vessel thrombus
About Segeberger Kliniken Gmbh
Segeberger Kliniken GmbH is a leading healthcare organization specializing in innovative clinical research and patient care. With a commitment to advancing medical science, the company conducts a range of clinical trials aimed at developing new therapies and improving treatment outcomes across various medical disciplines. Backed by a team of experienced professionals and state-of-the-art facilities, Segeberger Kliniken GmbH collaborates with academic institutions and industry partners to ensure the highest standards of clinical excellence and ethical practices. Their dedication to patient safety and scientific integrity positions them as a trusted sponsor in the field of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bad Segeberg, Schleswig Holstein, Germany
Patients applied
Trial Officials
Mohamed Abdel-Wahab, MD
Principal Investigator
Segeberger Kliniken GmbH
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials